| Document Date: 2009-03-31 14:08:55
Open Document File Size: 469,67 KBShare Result on Facebook
Company DOSAGE AND / GlaxoSmithKline / / Event FDA Phase / Product Issues / / Facility Laboratory Abnormalities / / IndustryTerm food / healthcare professional / / MedicalCondition IV heart failure / vascular disease / Macular edema / Patients With Congestive Heart Failure / chest pain / acute coronary syndromes / headache / Myocardial Ischemia Meta-Analysis / WARNINGS AND PRECAUTIONS Cardiac Failure AVANDIA / Cardiac Failure / symptomatic heart failure / dyspnea / myocardial infarction / peripheral neuropathy / unstable angina / angina pectoris / injury / diabetic ketoacidosis / Event Congestive heart failure / angina / coronary heart disease / cardiac arrest / hypoglycemia / upper respiratory tract infection / congestive heart failure / adjudicated fatal and nonfatal myocardial infarction / dyspnea / Carcinogenesis / stroke / active liver disease / emergent congestive heart failure / Diabetes / emergent myocardial ischemia / coronary artery disorder / myocardial infarction / diabetes mellitus / heart failure / coronary artery disease / coronary thrombosis / overt diabetes / long-standing diabetes / retinopathy / ischemic heart disease / anemia / myocardial ischemia / / MedicalTreatment drug therapy / / Organization New York Heart Association / DOSAGE AND ADMINISTRATION / FDA / / / Position Major / / Product AVANDAMET / gemfibrozil / rosiglitazone maleate / rifampin / Ramipril / FDA-Approved Medication / CHF medication / FDAapproved Medication / AVANDIA / rosiglitazone / glucose tolerance / AVANDIA® (rosiglitazone maleate) Tablets / fasting glucose / / Technology Pharmacokinetics / Pharmacodynamics / / URL www.fda.gov/medwatch / /
SocialTag |
• Coadministration of AVANDIA and insulin is not recommended. (1.2, 5.3) • Use of AVANDIA with nitrates is not recommended. (1.2, 5.2) ---------------------- DOSAGE AND ADMINISTRATION ---------------• Start at 4